Second malignancies among elderly survivors of cancer

Oncologist

Volumn 16, Issue 11, 2011, Pages 1572-1581

  Vanderwalde, Ari M ^a   Hurria, Arti ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Antineoplastic agents; Geriatrics; Neoplasms; Radiation induced lymphoma carcinoma; Second primary

Indexed keywords

BLEOMYCIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; PLACEBO; PREDNISONE; TAMOXIFEN; VINCRISTINE; VINDESINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVOR; COLORECTAL CANCER; DISEASE ASSOCIATION; GERIATRIC PATIENT; HODGKIN DISEASE; HORMONAL THERAPY; HUMAN; LIFE EXPECTANCY; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SECOND CANCER; UNITED STATES;

EID: 82355190581     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0214     Document Type: Review

References (75)

1. Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Edwards BK, Howe HL, Ries LA et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002;94: 2766-2792.
3. Ries LAG, Melbert D, Krapcho M et al., eds. SEER Cancer Statistics Review 1975-2005. Bethesda, MD: National Cancer Institute, 2008:31. Based on November 2007 SEER data submission, posted to the SEER Web site, 2008. Available at http://seer.cancer.gov/csr/1975_2005, accessed September 9, 2008.
4. Dong C, Hemminki K. Second primary neo plasms in 633,964 cancer patients in Sweden, 1958-1996. Int J Cancer 2001;93:155-161.
5. Travis LB. The epidemiology of second primary cancers. Cancer Epidemiol Biomarkers Prev 2006;15:2020-2026.
6. Ghelani D, Saliba R, Lima M. Secondary malignancies after hematopoietic stem cell trans- plantation. Crit Rev Oncol Hematol 2005;56: 115-126.
7. Allan JM, Travis LB. Mechanisms of therapy related carcinogenesis. Nat Rev Cancer 2005;5: 943-955.
8. Ng AV, Travis LB. Second primary cancers: An overview. Hematol Oncol Clin North Am 2008; 22:271-289.
9. Landier W, Bhatia S. Cancer survivorship: A pediatric perspective. The Oncologist 2008;13: 1181-1192.
10. Fraumeni JF Jr, Curtis RE, Edwards BK et al. Chapter 1: Introduction. In: Curtis R, Freedman D, Ron E et al., eds. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. Bethesda, MD: National Cancer Institute, 2006:1-9. NIH Publ. No. 05-5302.
11. Mauch PM, Kalish LA, Marcus KC et al. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am 1995;1: 33-42.
12. Travis LB, Rabkin CS, Brown LM et al. Cancer survivorship-genetic susceptibility and second primary cancers: Research strategies and recommendations. J Natl Cancer Inst 2006;98:15-25.
13. Hewitt M, Greenfield S, Stovall G, eds. From Cancer Patient to Cancer Survivor: Lost in Transition. National Cancer Policy Board Institute of Medicine and National Research Council of the National Archives. Washington DC: The National Academies Press, 2006:23-65.
14. Curtis R, Freedman D, Ron E et al., eds. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. NIH Publ. No. 05-5302. Bethesda, MD: National Cancer Institute, 2006:1-482.
15. Boice JD Jr, Harvey EB, Blettner M et al. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med 1992;326: 781-785.
16. Storm HH, Andersson M, Boice JD Jr et al. Adjuvant radiotherapy and risk of contralateral breast cancer. J Natl Cancer Inst 1992;84:1245-1250.
17. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 366:2087-2106.
18. Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: A population-based study. Int J Radiat Oncol Biol Phys 2003;56: 1038-1045.
19. Curtis RE, Boice JD Jr, Stovall M et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992;326: 1745-1751.
20. Smith RE, Bryant J, DeCillis A et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: The National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 2003;21:1195-1204.
21. Kirova YM, Vilcoq JR, Asselain B et al. Radiation induced sarcomas after radiotherapy for breast carcinoma: A large-scale single-institution review. Cancer 2005;104:856-863.
22. Rubino C, de Vathaire F, Shamsaldin A et al. Radiation dose, chemotherapy, hormonal treatment and risk of second cancer after breast cancer treatment. Br J Cancer 2003;89:840-846.
23. Roychoudhuri R, Evans H, Robinson D et al. Radiation-induced malignancies following radiotherapy for breast cancer. Br J Cancer 2004;91: 868-872.
24. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90:1371-1388.
25. Schaapveld M, Visser O, Louwman MJ et al. Risk of new primary nonbreast cancers after breast cancer treatment: A Dutch population-based study. J Clin Oncol 2008;26:1239-1246.
26. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999;91:1310-1316.
27. Li AJ, Karlan BY. Genetic factors in ovarian carcinoma. Curr Oncol Rep 2001;3:27-32.
28. Lynch HT, Lanspa S, Smyrk T et al. Hereditary nonpolyposis colorectal cancer (Lynch syndromes I & II). Genetics, pathology, natural history, and cancer control, Part I. Cancer Genet Cytogenet 1991;53:143-160.
29. Weinberg DS, Newschaffer CJ, Topham A. Risk for colorectal cancer after gynecologic cancer. Ann Intern Med 1999;131:189-193.
30. Travis LB, Curtis RE, Glimelius B et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995;87:524-530.
31. Travis LB, Holowaty EJ, Bergfeldt K et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999;340: 351-357.
32. Kaldor JM, Day NE, Pettersson F et al. Leu-kemia following chemotherapy for ovarian cancer. N Engl J Med 1990;322:1-6.
33. Neugut AI, Ahsan H, Robinson E et al. Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma. Cancer 1997; 79:1600-1604.
34. Chrouser K, Leibovich B, Bergstralh E et al. Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. J Urol 2005;174:107-110; discussion 110-111.
35. Brenner DJ, Curtis RE, Hall EJ et al. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 2000; 88:398-406.
36. Scélo G, Boffetta P, Hemminki K et al. Associations between small intestine cancer and other primary cancers: An international population-based study. Int J Cancer 2006;118:189-196.
37. Ronckers CM, McCarron P, Ron E. Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J Cancer 2005;117:281-288.
38. Mysliwiec PA, Cronin KA, Schatzkin A. Chapter 5: New malignancies following cancer of the colon, rectum, and anus. In: Curtis R, Freedman D, Ron E et al., eds. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. NIH Publ No 05-5302. Bethesda, MD: National Cancer Institute, 2006:111-144.
39. Giovannucci E. Modifiable risk factors for colon cancer. Gastroenterol Clin North Am 2002;31: 925-943.
40. Kendal WS, Nicholas G. A population-based analysis of second primary cancers after irradiation for rectal cancer. Am J Clin Oncol 2007;30:333-339.
41. van Leeuwen FE, Klokman WJ, Hagenbeek A et al. Second cancer risk following Hodgkin's disease: A 20-year follow-up study. J Clin Oncol 1994;12:312-325.
42. Dores GM, Coté TR, Travis LB. Chapter 16: New malignancies following Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloma. In: Curtis R, Freedman D, Ron E et al., eds. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. NIH Publ No 05-5302. Bethesda, MD: National Cancer Institute, 2006: 397-436.
43. Travis LB, Gospodarowicz M, Curtis RE et al. Lung cancer following chemotherapy and radio-therapy for Hodgkin's disease. J Natl Cancer Inst 2002;94:182-192.
44. Travis LB, Hill DA, Dores GM et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003;290:465-475.
45. Hodgson DC, Gilbert ES, Dores GM et al. Long-term solid cancer risk among 5-year survi- vors of Hodgkin's lymphoma. J Clin Oncol 2007; 25:1489-1497.
46. Rund D, Krichevsky S, Bar-Cohen S et al. Therapy-related leukemia: Clinical characteristics and analysis of new molecular risk factors in 96 adult patients. Leukemia 2005;19:1919-1928.
47. Howlader N, Noone A, Krapcho M et al., eds. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute. Based on November 2010 SEER data submission, posted to the SEER Web site, 2011. Available at http://seer. cancer.gov/csr/1975_2008, accessed August 23, 2011.
48. Deutsch M, Land SR, Begovic M et al. The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy. Results of National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials B-04 and B-06. Cancer 2003;98:1362-1368.
49. Patt DA, Duan Z, Fang S et al. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: Understanding risk. J Clin Oncol 2007;25:3871-3876.
50. Hershman D, Neugut AI, Jacobson JS et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007;99:196-205.
51. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus convention-ally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-1439.
52. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-1717.
53. Saadat M, Truong PT, Kader HA et al. Out-comes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer: Comparison of cohorts treated with and without tamoxifen. Cancer 2008;110:31-37.
54. Freedman DM, Curtis RE, Travis LB et al. Chapter 9: New malignancies following cancer of the uterine corpus or ovary. In: Curtis R, Freedman D, Ron E et al., eds. New Malignancies Among Cancer Survivors: SEER Cancer Regis- tries, 1973-2000. NIH Publ No 05-5302. Bethesda, MD: National Cancer Institute, 2006: 231-256.
55. Travis LB, Curtis RE, Boice JD Jr et al. Second malignant neoplasms among long-term survivors of ovarian cancer. Cancer Res 1996;56:1564-1570.
56. Houlston RS, Damato BE. Genetic predis- position to ocular melanoma. Eye (Lond) 1999; 13:43-46.
57. Kaldor JM, Day NE, Kittelmann B et al. Bladder tumours following chemotherapy and radiotherapy for ovarian cancer: A case-control study. Int J Cancer 1995;63:1-6.
58. Moon K, Stukenborg GJ, Keim J et al. Cancer incidence after localized therapy for prostate cancer. Cancer 2006;107:991-998.
59. McCredie M, Macfarlane GJ, Bell J et al. Second primary cancers after cancers of the colon and rectum in New South Wales, Australia, 1972-1991. Cancer Epidemiol Biomarkers Prev 1997;6:155-160.
60. Hoar SK, Wilson J, Blot WJ et al. Second cancer following cancer of the digestive system in Connecticut, 1935-82. Natl Cancer Inst Monogr 1985;68:49-82.
61. Hoppe RT. Hodgkin's disease: Complications of therapy and excess mortality. Ann Oncol 1997; 8(suppl 1):115-118.
62. Ng AK, Bernardo MV, Weller E et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: Long-term risks and risk factors. Blood 2002;100: 1989-1996.
63. Bhatia S, Yasui Y, Robison LL et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: Report from the Late Effects Study Group. J Clin Oncol 2003;21:4386-4394.
64. Travis LB, Fossa SD, Schonfeld SJ et al. Second cancers among 40,576 testicular cancer patients: Focus on long-term survivors. J Natl Cancer Inst 2005;97:1354-1365.
65. Brusamolino E, Baio A, Orlandi E et al. Long-term events in adult patients with clinical stage IA- IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: A single-institution 15-year follow-up. Clin Cancer Res 2006;12:6487-6493.
66. Tward JD, Wendland MM, Shrieve DC et al. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 2006;107:108-115.
67. Mudie NY, Swerdlow AJ, Higgins CD et al. Risk of second malignancy after non-Hodgkin's lymphoma: A British Cohort Study. J Clin Oncol 2006;24:1568-1574.
68. André M, Mounier N, Leleu X et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: A GELA cohort study on 2837 patients. Blood 2004;103:1222-1228.
69. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Breast Cancer Screening and Diagnosis, Version Available at http://www.nccn.org/professionals/ physician_gls/pdf/breast-screening.pdf, accessed April 12, 2011.
70. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Breast Cancer, Version 2.2011. Available at http://www.nccn.org/professionals/physician_gls/pdf/ breast.pdf. accessed April 12, 2011.
71. Khatcheressian JL, Wolff AC, Smith TJ et al. American Society of Clinical Oncology 2006 up-date of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 2006;24:5091-5097.
72. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Hodgkin Lymphoma, Version 2.2011. Available at http://www.nccn.org/professionals/physician_gls/ pdf/hodgkins.pdf, accessed May 6, 2011.
73. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Colon Cancer, Version 3.2011. Available at http://www.nccn.org/professionals/physician_gls/pdf/ colon.pdf, accessed May 6, 2011.).
74. Grady WM, Russell K. Ionizing radiation and rectal cancer: Victims of our own success. Gastroenterology 2005;128:1114-1117.
75. Walter LC, Covinsky KE. Cancer screening in elderly patients: A framework for individualized decision making. JAMA 2001;2750-2756.